Enoxaparin sodium biosimilar - Harvest Moon Pharmaceuticals

Drug Profile

Enoxaparin sodium biosimilar - Harvest Moon Pharmaceuticals

Latest Information Update: 22 Aug 2013

Price : $50

At a glance

  • Originator Harvest Moon Pharmaceuticals
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction; Thromboembolism; Unstable angina pectoris

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Aug 2013 Launched for Myocardial infarction in Latin America (SC)
  • 22 Aug 2013 Launched for Thromboembolism (prevention) in Latin America (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top